British healthcare REIT Assura has received a 1.5 billion pound ($1.96 billion) indicative cash-and-stock bid from Primary ...

Jazz Pharmaceuticals plc has a 12-month low of $99.06 and a 12-month high of $148.06. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74.

LONDON, GB / ACCESS Newswire / March 31, 2025 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, announces that the ...

Jazz Pharmaceuticals plc has a 52 week low of $99.06 and a 52 week high of $148.06. The firm has a 50 day moving average of $132.36 and a 200-day moving average of $122.78.

Avadel Pharmaceuticals PLC (AVDL) reports a significant increase in revenue and achieves cash flow positivity, while projecting robust growth for 2025 despite ongoing challenges. DUBLIN (AP ...

LONDON, GB / ACCESS Newswire / March 31, 2025 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, announces that the ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Doug Long, BA, MBA, vice president of Industry Relations at IQVIA, shares what's happening in the growing GLP-1 and biosimilars space. Long was a presenter at the annual AMCP 2025 meeting in Houston, ...